Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biogen Idec (NQ:BIIB)

136.36 -2.95 (-2.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
53 54 Next >
Biogen Inc. Surpasses Q3 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $4.77 per share. 
Via Talk Markets
Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition
 
Via Benzinga
Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug
Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month. 
Via Investor's Business Daily
Recap: Biogen Q3 Earnings
Biogen (NASDAQ:BIIB) reported its Q3 earnings results on Tuesday, October 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Biogen beat estimated earnings by... 
Via Benzinga
Earnings Scheduled For October 25, 2022
Companies Reporting Before The Bell • UBS Gr (NYSE:UBS) is expected to report earnings for its third quarter. • SAP (NYSE:SAP) is expected to report earnings for its third quarter. 
Via Benzinga
Where Biogen Stands With Analysts
Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Biogen Q3 Earnings Preview: Key Items For Investors To Watch
Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing 
Via Benzinga
15 Analysts Have This to Say About Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter: 
Via Benzinga
Biogen To Report Q3 Earnings: Here's What To Expect
Biogen will report third-quarter 2022 results on Oct 25, before market open. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.47% on an annualized basis producing an average annual return of 9.66%. Currently, Biogen has a market capitalization of... 
Via Benzinga
Earnings Preview: Biogen
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-10-25. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an... 
Via Benzinga
3 Alzheimer's Therapy Stocks to Invest in
Alzheimer's treatments could make a big winner of these stocks. 
Via The Motley Fool
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund. 
Via The Motley Fool
Where Will Biogen Be in 5 Years?
Is this biotech an investment worth buying and holding today? 
Via The Motley Fool
FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug
 
Via Benzinga
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
 
Via Benzinga
Biogen Whale Trades For October 20
A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 12 strange trades. 
Via Benzinga
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Biogen's Stock Pullback Offers a Second Chance
Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive. 
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
From Biogen Inc.
Via GlobeNewswire
This Is What Whales Are Betting On Biogen
Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's. 
Via Benzinga
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity
Even a percentage of the Alzheimer's market could mean $7 billion for Biogen. 
Via Investor's Business Daily
GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®
From GoodRx
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13
Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside. 
Via Talk Markets
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.